Abstract:Objective: To observe the efficacy and safety of leflunomide combined with prednisone therapy (LEF therapy) in the treatment of patients with adult onset steroid-dependent and steroid-resistant minimal change disease (MCD). Methods: 16 MCD patients who had been treated with LEF therapy were retrospectively analyzed. 87.5% (14/16) of the patients were steroid-dependent and 12.5% (2/16) of the patients were steroid-resistant. The initial dose of LEF was 10 - 20 mg/day combined with prednisone 0.25 - 1.0 mg/kg/day, gradually tapering after 8 weeks. Clinical and laboratory data at baseline, 2nd, 4th, 8th, 12th, 24th, and 48th week were analyzed compared with initial course of prednisone monotherapy (FRED monotherapy) and cyclophosphamide combined with prednisone therapy (CTX therapy). Results: All the 16 patients achieved different levels of remission in LEF therapy. 93.8% (15/16) of the patients, including the two steroid-resistant patients, achieved complete remission. During the treatment, 8 patients had adverse effects which could be well tolerated. Compared LEF therapy with PRED monotherapy (n = 16), the dose of prednisone to maintain remission was reduced (from median 22.5 mg/day to median 7.5 mg/day, p = 0.041); relapse rate during the follow-up decreased from 100% to 31.3% (p = 0.002); the median time before relapse increased from 20.3 weeks to 32.5 weeks. Compared LEF therapy with CTX therapy (n = 12), the dose of prednisone to maintain remission was reduced significantly (from median 22.5 mg/day to median 5.0 mg/day, p = 0.003); relapse rate during the follow-up decreased from 100% to 31.3% (p = 0.001); the median time before relapse increased from 11.7 weeks to 32.5 weeks. Conclusions: LEF therapy seems to be effective in steroid-resistant and steroid-dependent MCD. This therapy may reduce the amount of preclnisone to maintain remission and reduce the relapse rate compared with PRED monotherapy and CTX therapy. LEF therapy was usually well tolerated.

Osteoclast Differentiation Inhibited by Active Metabolite of Leflunomide through Regulating NFATc1 Expression

Effect of Teriflunomide Combined with Methotrexate on Fibroblast-like Synoviocytes in Rheumatoid Arthritis

Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells.

A 771726, the Active Metabolite of Leflunomide, Inhibits TNF-α and IL-1 from Kupffer Cells

[Effects of Leflunomide and Its Active Metabolite on the Production and Mrna Expression of TNF-alpha in Peritoneal Macrophages and Synovial Cells with Adjuvant Arthritis in Rats].

Leflunomide attenuates hepatocyte injury by inhibiting Kupffer cells.

The Mitochondria-Independent Cytotoxic Effect of Leflunomide on RPMI-8226 Multiple Myeloma Cell Line

Effect of leflunomide on Th1/Th2 balance in the peripheral blood and joint function of patients with rheumatoid arthritis

Mitochondrial Dysfunction Induced by Leflunomide and Its Active Metabolite.

Endoplasmic Reticulum Stress and MAPK Signaling Pathway Activation Underlie Leflunomide-Induced Toxicity in HepG2 Cells.

Leflunomide Induces Immunosuppression in Collagen-Induced Arthritis Rats by Upregulating CD4+CD25+ Regulatory T Cells.

Effect of Leflunomide on Immunological Liver Injury in Mice

Antidepressant effect of teriflunomide via oligodendrocyte protection in a mouse model

Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis

Inhibitory Effect Of Leflunomide On Hepatic Fibrosis Induced By Ccl4 In Rats

Efficacy and safety of leflunomide in treatment of steroid-dependent and steroid-resistant adult onset minimal change disease.

Leflunomide Versus Cyclophosphamide in the Induction Treatment of Proliferative Lupus Nephritis in Chinese Patients: a Randomized Trial.

The Potential Role of Leflunomide in Inhibiting Vascular Fibrosis by Down-Regulating Type-Ii Macrophages in Takayasu's Arteritis.

HIF1α Inhibition Facilitates Leflunomide-AHR-CRP Signaling to Attenuate Bone Erosion in CRP-aberrant Rheumatoid Arthritis.

Leflunomide, a New Disease-Modifying Drug for Treating Active Rheumatoid Arthritis in Methotrexate-Controlled Phase II Clinical Trial.

Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study.